Berberine With MK-677: Two Separate Signals, No Combination Trial

A CYP Finding Is Not Yet an Ibutamoren Interaction

Ying Guo and colleagues tested berberine against five probe drugs in a randomized crossover study. Seventeen healthy Chinese men completed both phases after two weeks of repeated berberine or placebo exposure. Their abstract concludes:

“Repeated administration of berberine (300 mg, t.i.d., p.o.) decreased CYP2D6, 2C9, and CYP3A4 activities.”

The authors were pharmacology and clinical pharmacogenetics investigators at Central South University and the University of Kansas Medical Center. The excerpt documents an effect on probe-drug phenotypes under that study's conditions. It does not show that ibutamoren is a clinically important substrate, quantify a berberine–ibutamoren exposure change, or endorse either product (PMID 21870106; PMCID PMC4898966; DOI 10.1007/s00228-011-1108-2).

FDA's 2024 ibutamoren review found only limited human pharmacokinetic description and did not identify additional PK literature. Without a characterized metabolic contribution, an interaction cannot responsibly be labeled “major,” “minor,” or neutral from the berberine probe study alone (FDA review, PDF pages 37–38).

The Combination Claim Audit

The Glucose Signals Point in Opposite Directions—but Do Not Cancel Algebraically

In an eight-week randomized trial of 24 men with obesity, ibutamoren increased GH and IGF-1 and fat-free mass, but oral glucose-tolerance testing showed impaired glucose homeostasis at weeks two and eight (PMID 9467542; DOI 10.1210/jcem.83.2.4539). In the longer healthy older-adult trial, fasting glucose increased and insulin sensitivity decreased (PMID 18981485; PMCID PMC2757071). These are population-specific findings, not a universal event rate.

Berberine systematic reviews report glucose-related effects across heterogeneous trials in people with metabolic disease. Those trials did not include ibutamoren, and supplement preparations, comparators, and study quality varied (PMID 25498346).

Combining two substances does not permit subtracting one trial's average change from another trial's average change. Different populations, products, endpoints, and durations make that arithmetic invalid.

What the Legacy Protocol Got Wrong

The previous article declared the combination acceptable, assigned a two-hour separation window, proposed laboratory intervals, and treated berberine as a glucose countermeasure. None of those instructions came from a direct combination study.

Separating doses by two hours may change simultaneous gut exposure, but it does not erase enzyme modulation that was measured after two weeks of repeated berberine. Conversely, the CYP probe result cannot establish that separating the products is useless; no ibutamoren comparison exists. The honest answer is that timing has not been validated.

The food and supplement evidence page maps the broader interaction gap. The young-adult safety review separates observed metabolic findings from unmeasured incidence, and the exercise audit shows why metabolic and body-composition signals are not performance outcomes.

What a Direct Study Would Need

A useful interaction trial would identify both products, compare ibutamoren exposure with and without repeated berberine, measure glucose and insulin over a defined interval, record adverse events, and prespecify whether timing changes any result. It would also report the tested populations and formulations clearly enough to judge transferability.

Until then, “synergy,” “cancellation,” “avoid,” and “take two hours apart” are stronger statements than the evidence supports. Anyone already using both should give a clinician the exact labels, amounts, timing, and any glucose data; this is an exposure record, not a self-directed protocol.

Medical review of this revision is pending. FDA, investigators, institutions, journals, and study authors do not endorse berberine, ibutamoren, HealthRX.com, or this page.